BHLHE40 is a basic helix-loop-helix transcriptional repressor with central roles in circadian rhythm regulation and emerging functions in immune and cancer biology. In circadian physiology, BHLHE40 forms part of the DEC autoregulatory feedback loop that represses clock-controlled genes by competing with CLOCK-BMAL1 for E-box binding sites, while being reciprocally repressed by PER and CRY proteins 12. Beyond circadian functions, BHLHE40 regulates cardiovascular physiology through ATP1B1 repression, controlling blood pressure rhythmicity 3. In immune contexts, BHLHE40 drives pro-inflammatory and pro-tumorigenic cell states. It promotes CD4+ tissue-resident memory T cell differentiation and function through HLF-mediated regulation 4, enhances TH1-like cell populations in colorectal cancer with favorable immunotherapy responses 5, and directs neutrophil polarization toward immunosuppressive, glycolytic phenotypes in pancreatic cancer 6. BHLHE40 also functions as a master regulator of epithelial-mesenchymal transition (EMT) in metastatic colorectal cancer, promoting cancer cell invasion and liver metastasis 7. Additionally, BHLHE40 inhibits ferroptosis in pancreatic cancer by upregulating SREBF1, enhancing lipid metabolism-mediated protection 8. In contrast, BHLHE40/41 reduction in macrophages and microglia increases cholesterol clearance and lysosomal capacity, potentially benefiting neurodegenerative diseases 9. These diverse functions establish BHLHE40 as a pleiotropic transcriptional regulator with context-dependent roles in homeostasis and disease.